Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-094544
Filing Date
2026-08-12
Accepted
2026-08-12 08:40:46
Documents
44
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20260630x10q.htm   iXBRL 10-Q 1580593
2 EX-31.1 apre-20260630xex31d1.htm EX-31.1 10244
3 EX-31.2 apre-20260630xex31d2.htm EX-31.2 10712
4 EX-32.1 apre-20260630xex32d1.htm EX-32.1 6464
5 EX-32.2 apre-20260630xex32d2.htm EX-32.2 6887
  Complete submission text file 0001104659-26-094544.txt   4401880

Data Files

Seq Description Document Type Size
6 EX-101.SCH apre-20260630.xsd EX-101.SCH 27876
7 EX-101.CAL apre-20260630_cal.xml EX-101.CAL 28814
8 EX-101.DEF apre-20260630_def.xml EX-101.DEF 102756
9 EX-101.LAB apre-20260630_lab.xml EX-101.LAB 251242
10 EX-101.PRE apre-20260630_pre.xml EX-101.PRE 171791
48 EXTRACTED XBRL INSTANCE DOCUMENT apre-20260630x10q_htm.xml XML 404903
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 215-948-4119
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 261265453
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)